ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005252

heart failure

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. heart failure. Diseases, record MONDO_0005252. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005252

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
heart failure
Open Targets
Open Targets ID
MONDO_0005252
Open Targets
Other names
Heart failure (disorder), Heart failure NOS, Heart failure NOS (disorder), Heart failure, unspecified, Heart: [weak] or [failure NOS], Weak heart, cardiac dysfunction, cardiac failure, cardiac insufficiency, failure, heart, insufficiency, Cardiac
Open Targets
MeSH
D006333
MeSH
NCI Thesaurus
C50577
NCI Thesaurus
Highest stage of its drugs
Approval, for 46 of its 311 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs311

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
DAPAGLIFLOZINCHEMBL429910Small moleculeApprovalEMA Human Drugs656262Drugs and targets
EMPAGLIFLOZINCHEMBL2107830Small moleculeApprovalEMA Human Drugs626161Drugs and targets
VALSARTANCHEMBL1069Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD855553Drugs and targets
SACUBITRILCHEMBL3137301Small moleculeApprovalDailyMed, EMA Human Drugs and TTD565151Drugs and targets
SPIRONOLACTONECHEMBL1393Small moleculeApprovalDailyMed and EMA Human Drugs272424Drugs and targets
CARVEDILOLCHEMBL723Small moleculeApprovalDailyMed311916Drugs and targets
IVABRADINECHEMBL471737Small moleculeApprovalEMA Human Drugs and FDA251818Drugs and targets
FINERENONECHEMBL2181927Small moleculeApprovalEMA Human Drugs141313Drugs and targets
DIGOXINCHEMBL1751Small moleculeApprovalDailyMed and TTD151212Drugs and targets
VERICIGUATCHEMBL4066936Small moleculeApprovalDailyMed, EMA Human Drugs, FDA and TTD151111Drugs and targets

1 to 10 of 311

See all 311 drugs

Targets243

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRB1Adrenergic receptor13Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/153Drugs and targets
ADRB2Adrenergic receptor11Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/154Drugs and targets
ACEAngiotensin-converting enzyme10Angiotensin-converting enzyme inhibitorApprovalhttps://conductscience.org/library/genes/1636Drugs and targets
AGTR1Type-1 angiotensin II receptor8Type-1 angiotensin II receptor antagonistApprovalhttps://conductscience.org/library/genes/185Drugs and targets
GUCY1A1Soluble guanylate cyclase8Soluble guanylate cyclase activatorApprovalhttps://conductscience.org/library/genes/2982Drugs and targets
GUCY1A2Soluble guanylate cyclase8Soluble guanylate cyclase activatorApprovalhttps://conductscience.org/library/genes/2977Drugs and targets
GUCY1B1Soluble guanylate cyclase8Soluble guanylate cyclase activatorApprovalhttps://conductscience.org/library/genes/2983Drugs and targets
SLC5A2Sodium/glucose cotransporter 28Sodium/glucose cotransporter 2 inhibitorApprovalhttps://conductscience.org/library/genes/6524Drugs and targets
ADORA1Adenosine receptor5Adenosine A1 receptor agonist; Adenosine A1 receptor antagonist; Adenosine receptor agonistPhase 3https://conductscience.org/library/genes/134Drugs and targets
ADRA1AAdrenergic receptor5Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonistApprovalhttps://conductscience.org/library/genes/148Drugs and targets

1 to 10 of 243

See all 243 targets

Trials708

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 29 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03817463A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes327,6242024-09-23Diabetes Mellitus, Type 2DEXTROSE, EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT02929329Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionPhase 38,2562021-07-20Heart FailureOMECAMTIV MECARBILIts record names the diseaseClinicalTrials.gov
NCT00475852A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailurePhase 37,1412012-05-10Heart DecompensationNESIRITIDEIts record names the diseaseClinicalTrials.gov
NCT00853658Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailurePhase 37,0642016-11-25Chronic Heart FailureALISKIREN, ENALAPRILIts record names the diseaseClinicalTrials.gov
NCT01870778Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFPhase 36,6002018-03-30Acute Heart FailureSERELAXINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT02441218Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre StudyPhase 36,5052015-06-29Chronic Heart FailureIVABRADINEIts record names the diseaseClinicalTrials.gov
NCT03619213Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.Phase 36,2632023-07-11Heart Failure With Preserved Ejection FractionDAPAGLIFLOZINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT05093933A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)Phase 36,1062025-12-19Chronic Heart Failure With Reduced Ejection FractionVERICIGUATIts record names the diseaseClinicalTrials.gov
NCT04435626
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Phase 36,0162025-08-26Heart FailureFINERENONEIts record names the diseaseClinicalTrials.gov
NCT03057951EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)Phase 35,9882022-06-06Heart FailureEMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov

1 to 10 of 708

See all 708 trials

Comparisons in its trials263

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause1,371 of 163,8122,524 of 163,812327,624NCT03817463Trial comparisons
Omecamtiv Mecarbil vs Placebo: deaths from any cause1,078 of 4,1201,078 of 4,1128,232NCT02929329Trial comparisons
Omecamtiv Mecarbil vs Placebo: serious adverse events2,373 of 4,1102,435 of 4,1018,211NCT02929329Trial comparisons
Nesiritide vs Placebo: Number of Patients With Renal Impairment1,032 of 3,498968 of 3,5097,007NCT00475852Trial comparisons
Nesiritide vs Placebo: All-Cause Mortality Through Day 30126 of 3,498141 of 3,5097,007NCT00475852Trial comparisons
Nesiritide vs Placebo: All-Cause Mortality Through Day 180429 of 3,498447 of 3,5097,007NCT00475852Trial comparisons
Nesiritide vs Placebo: serious adverse events5 of 3,4982 of 3,5097,007NCT00475852Trial comparisons
Nesiritide vs Placebo: Composite of Persistent or Worsening Heart Failure and All-Cause Mortality147 of 3,459165 of 3,4626,921NCT00475852Trial comparisons
Nesiritide vs Placebo: Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality372 of 3,423402 of 3,4156,838NCT00475852Trial comparisons
Nesiritide vs Placebo: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality321 of 3,423345 of 3,4136,836NCT00475852Trial comparisons

1 to 10 of 263

See all 263 comparisons in its trials

Papers from its trials905

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
40897189RESULT1PubMed
40695536RESULT1PubMed
40689152RESULT1PubMed
39948072RESULT1PubMed
39934967RESULT1PubMed
39473305RESULT1PubMed
39353506RESULT1PubMed
39232490RESULT1PubMed
39225278RESULT1PubMed
39218030RESULT1PubMed

1 to 10 of 905

See all 905 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005252

GET https://conductscience.org/api/diseases/v1/MONDO_0005252/drugs?page=2

API referenceFor AI assistants